scholarly journals Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ

Cancer ◽  
2016 ◽  
Vol 123 (6) ◽  
pp. 940-947 ◽  
Author(s):  
Hui Zhao ◽  
Nainan Hei ◽  
Yiling Wu ◽  
Winston Chan ◽  
Xiudong Lei ◽  
...  
Keyword(s):  
Aromatase Inhibitor ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Elderly Women ◽  
Ductal Carcinoma ◽  
Inhibitor Therapy ◽  
Aromatase Inhibitor Therapy

Ductal carcinoma in situ (DCIS) in elderly women. Results according to treatment

2004 ◽  
Vol 2 (3) ◽  
pp. 189 ◽  
Author(s):  
B Cutuli ◽  
C Lemanski ◽  
C Cohen-Solal-Le Nir ◽  
B De Lafontan ◽  
L Gonzague-Casabianca ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Elderly Women ◽  
Ductal Carcinoma

scholarly journals Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy

2016 ◽  
Author(s):  
Stephen Kinsey-Trotman ◽  
Zumin Shi ◽  
Beverley Fosh
Keyword(s):  
Aromatase Inhibitor ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Meta Analysis ◽  
Tamoxifen Treatment ◽  
Breast Cancers ◽  
Aromatase Inhibitor Treatment ◽  
Treatment Naïve

This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.

Sign in / Sign up

Export Citation Format

Share Document